Triheptanoin Dosage

Medically reviewed by Drugs.com. Last updated on Sep 14, 2023.

Usual Adult Dose for Functional Gastric Disorder

Recommended total daily dose (mL) = patients DCI (kcal) x target % dose of DCI / 8.3 kcal/mL

• Round to nearest whole number
• Divide total daily dose into at least 4 approximately equal individual doses

Dose Initiation/Titration:

Patients not currently taking a medium chain triglyceride (MCT) product:

• Initiate at approximately 10% DCI divided into at least 4 individual doses.
• Increase to recommended total daily dose over 2 to 3 weeks.

Patients switching from another MCT product:

• Discontinue previous MCT before therapy initiation.
• Initiate at last tolerated MCT dose divided into at least 4 individual doses.
• Increase total daily dosage by approximately 5% DCI every 2 to 3 days until target dosage is achieved.

Comments:

• Assess metabolic requirements by determining daily caloric intake (DCI) prior to dose calculations.
• Recommended target is 35% of DCI.
• Caloric value of this product is 8.3 kcal/mL.

Use: As a source of calories and fatty acid in patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Usual Pediatric Dose for Functional Gastric Disorder

Recommended total daily dose (mL) = patients DCI (kcal) x target % dose of DCI / 8.3 kcal/mL

• Round to nearest whole number
• Divide total daily dose into at least 4 approximately equal individual doses

Dose Initiation/Titration:

Patients not currently taking a medium chain triglyceride (MCT) product:

• Initiate at approximately 10% DCI divided into at least 4 individual doses.
• Increase to recommended total daily dose over 2 to 3 weeks.

Patients switching from another MCT product:

• Discontinue previous MCT before therapy initiation.
• Initiate at last tolerated MCT dose divided into at least 4 individual doses.
• Increase total daily dosage by approximately 5% DCI every 2 to 3 days until target dosage is achieved.

Comments:

• Assess metabolic requirements by determining daily caloric intake (DCI) prior to dose calculations.
• Recommended target is 35% of DCI.
• Caloric value of this product is 8.3 kcal/mL.
• Neonates may require a higher fat intake and thus an increased dose of this product; consider current nutritional recommendations when dosing in this population.

Use: As a source of calories and fatty acid in patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Dose Adjustments

Gastrointestinal Adverse Reactions:

• Consider dose reduction until symptoms resolve.
• If unable to achieve target dosage (up to 35% of daily caloric intake), maintain at maximum tolerated dose

Precautions

CONTRAINDICATIONS: None

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• Administer at mealtimes or with snacks or via a feeding tube.
• To avoid gastrointestinal upset, do not administer alone.

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

Monitoring:

• Monitor total caloric intake during dose titration, especially if gastrointestinal adverse reactions occur; adjust all components of diet as needed.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer